✦ LIBER ✦

A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction

✍ Scribed by Wayne J.G. Hellstrom; Matthew T. Freier; Ege Can Serefoglu; Ronald W. Lewis; Karen DiDonato; Craig A. Peterson

Book ID: 115199810
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 399 KB
Volume: 111
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2012.11267.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of topical WBI-1001

Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial

✍ R. Bissonnette; C. Bolduc; C. Maari; S. Nigen; J.M. Webster; L. Tang; M. Lyle 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

Double-blind, placebo-controlled evaluat

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

✍ Diamond, L E; Earle, D C; Rosen, R C; Willett, M S; Molinoff, P B 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 128 KB

A phase IV randomized, double-blind, pla

A phase IV randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efalizumab in patients with moderate to severe plaque psoriasis involving the scalp

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre